<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6A4932AE-EC6A-433B-906C-45504186D303"><gtr:id>6A4932AE-EC6A-433B-906C-45504186D303</gtr:id><gtr:name>Ipsen Biopharm Limited</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Wrexham Industrial Estate</gtr:line2><gtr:postCode>LL13 9UF</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6A4932AE-EC6A-433B-906C-45504186D303" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>6A4932AE-EC6A-433B-906C-45504186D303</gtr:id><gtr:name>Ipsen Biopharm Limited</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Wrexham Industrial Estate</gtr:line2><gtr:postCode>LL13 9UF</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>221621.0</gtr:offerGrant><gtr:projectCost>443241.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A40B05D5-27FA-4B57-84A3-3A31B4A08087" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A40B05D5-27FA-4B57-84A3-3A31B4A08087</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>WILTON CENTRE , WILTON,</gtr:line1><gtr:city>REDCAR</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>353510.0</gtr:offerGrant><gtr:projectCost>353510.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60A3D4AD-10FC-4B81-B06C-AC94F3AE2F21" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>60A3D4AD-10FC-4B81-B06C-AC94F3AE2F21</gtr:id><gtr:name>Touchlight Genetics Limited</gtr:name><gtr:address><gtr:line1>40 QUEEN ANNE STREET</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>W1G 9EL</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>289475.0</gtr:offerGrant><gtr:projectCost>413535.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BC0BADF0-90AF-440B-A057-ED2C11FEA782"><gtr:id>BC0BADF0-90AF-440B-A057-ED2C11FEA782</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Gruber</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=104201"><gtr:id>334A0E64-0B74-4156-8778-E39D4F57AB6A</gtr:id><gtr:title>Novel production process for a highly potent recombinant protein using doggybone DNA (dbDNA) vector and cell free expression technology</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>104201</gtr:grantReference><gtr:abstractText>Toxic medicines are becoming a major focus of the pharmaceutical industry, as high potency products need minimal amounts to dose patients and so material requirements are low. However, the associated risks of working with these toxic products can make their development problematic, and traditional manufacturing routes are often unsuitable. This project will examine using cell free expression to produce a botulinum toxin from a &amp;quot;doggybone DNA&amp;quot; (dbDNA) vector. The project will develop a closed loop system for producing dbDNA, and screen a wide range of conditions to optimise a cell free expression system, for enclosed processing of toxins to negate the health and safety risks and technical yield limitations associated with high potency biopharmaceutical production. The project is a collaboration led by Ipsen Biopharm, involving Touchlight Genetics and the Centre for Process Innovation.</gtr:abstractText><gtr:fund><gtr:end>2020-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2018-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>864606</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">104201</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>